BME · ROVI.MC
Laboratorios Farmaceuticos Rovi, S.A.
€61.55+€0.25 (+0.41%)
Laboratorios Farmaceuticos Rovi, S.A.’s quoted price sits in the lower half of its reported 52-week range, 29.01% below the high.
Loading market information…
BME · PHM.MC · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Pharma Mar, S.A.’s quoted price sits in the lower half of its reported 52-week range, 34.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Pharma Mar, S.A.’s forward annual dividend is €1.00 per share, paid annual. The forward yield is 1.44% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pharma Mar, S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Feb 28, 2025 | €1.05+8.25% vs estimate | €48.00M+11.89% vs estimate |
|---|
| Q3 2024 | Oct 29, 2024 | €0.21+2.44% vs estimate | €45.70M-0.16% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€61.55+€0.25 (+0.41%)
Laboratorios Farmaceuticos Rovi, S.A.’s quoted price sits in the lower half of its reported 52-week range, 29.01% below the high.
€10.52+€0.10 (+0.96%)
Almirall, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
€4.78+€0.04 (+0.74%)
Faes Farma, S.A.’s quoted price sits in the lower half of its reported 52-week range, 12.22% below the high.
€53.80€0.00 (0.0%)
Clínica Baviera, S.A.’s quoted price sits in the upper half of its reported 52-week range, 13.23% below the high.
€12.45€0.00 (0.0%)
Prim, S.A.’s quoted price sits in the lower half of its reported 52-week range, 10.75% below the high.
€2.57+€0.03 (+1.18%)
Laboratorio Reig Jofre, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.41% below the high.
€2.50+€0.00 (+0.16%)
Oryzon Genomics S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.39% below the high.
€2.63€0.00 (0.0%)
Atrys Health, S.A.’s quoted price sits in the lower half of its reported 52-week range, 21.49% below the high.
